Guardant的这一测试方法名为Shield，自2022年以来一直在美国供实验室使用，费用为895美元，但不包括在医疗保险范围内。 Talasaz预计Shield将在不久的 ...

Guardant Health (NASDAQ:GH) said its recently approved blood test Shield for the detection of colorectal cancer has been commercially launched in the U.S. The diagnostics maker said Medicare will ...

Guardant Health (GH) announced the National Cancer Institute, or NCI, has selected the company’s Shield multi-cancer detection test for use in its Vanguard study, which will address the ...

--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ multi-cancer ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...